Effect of IV Lidocaine Infusions on Pain

Not Applicable

Completed

• Conditions: Pain
• Interventions: Drug: Intravenous lidocaine

• Registration Number: NCT00725504
• Lead Sponsor: Stanford University

Brief Summary

Our goals for this study involve using intravenous lidocaine as it is normally used in the Stanford Pain Management Center to assess the effect of intravenous lidocaine on chronic pain. Studies have been done determining the efficacy of intravenous lidocaine for treating pain but little research has been done to determine the effects of an intravenous lidocaine infusion on the different components of the pain experience. Our study will incorporate pain quality measures both before and during the infusions of lidocaine to determine changes in present pain intensity.

Detailed Description

Each patient will receive an intravenous infusion of lidocaine. Drug will be infused using a computer-controlled paradigm. This paradigm allows increasing plasma concentrations in a step-wise manner, keeping the concentration during each infusion step constant. Plasma concentrations will be increased gradually from 0 to 5 ug/ml in a method at the discretion of the medical team. This will be conducted according to standard medical practice for the infusion and the study procedures will not affect the infusion paradigm. Total infusion time is approximately 1-2 hours. During the course of the study, the primary outcome measure was changed from blood oxygenation level dependent (BOLD) signal to pain intensity.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2008-07-28
• Study First Submitted QC: 2008-07-28
• Study First Posted: 2008-07-30
• Study Start: 2008-09
• Primary Completion: 2011-01
• Study Completion: 2011-02
• Results First Submitted: 2017-03-04
• Results First Submitted QC: 2017-03-04
• Results First Posted: 2017-04-17
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-24
• Last Update Posted: 2019-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

• subjects between the ages of 18 and 100 years for clinical component; subjects between the ages of 18 and 70 for the MRI component

• meets the study criteria of chronic pain of either peripheral or central origin
• male or a non-pregnant, non-lactating female. If females are of reproductive potential (i.e., not surgically sterilized and/or not post menopausal), they must be practicing an accepted method of birth control, agree to a urine pregnancy test at the start of each study session (for patient scheduled through the clinic, this has already been addressed by the recommending physician)
• is not currently on a sodium channel blocking agent, anticonvulsant, or tricyclic antidepressant,
• must be able to comply with any other study requirements and complete experimental tasks
• have no reported substance abuse within the past six months;

Read More

Exclusion Criteria

• subject is lactating or pregnant;

• subject suffers from clinically significant cardiac, pulmonary, renal or liver disease;
• subject allergic to lidocaine.
• MRI Component: any metal objects (especially surgical clips), devices, or implants or any other MRI contraindication

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lidocaine infusion	Intravenous lidocaine	Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.

Primary Outcome Measures

Name	Time	Method
Present Pain Intensity	Patients completed the VAS of present pain intensity immediately before and immediately after placebo and during each infusion level	Present pain intensity was measured using the visual analog scale (VAS). This is scored between 0 (no pain) to 10 (worst possible pain).

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States